Understanding NK cells in ALS

By examining gene activity, researchers aim to uncover new therapy targets in ALS.

Author | Shoshanna Fischhoff

Natural killer (NK) cells are a type of immune cell that helps the body fight infections and clear out abnormal cells.  However, researchers have shown that in amyotrophic lateral sclerosis (ALS) dysregulated NK cells are capable of damaging motor neurons, associating them with ALS progression.  However, exactly how this happens remains unclear.

Researchers led by Stephen Goutman, M.D., M.S., Harriet Hiller Research Professor, and Benjamin Murdock, Ph.D., Robert A. Epstein and Joan M. Chernoff-Epstein Emerging Scholar, examined NK cell gene expression in ALS patients. Their goal was to discover specific dysregulated genes and pathways over the course of the disease in an effort to identify potential new therapy targets. Their results were recently published in Neurology Open Access.

“We compared blood samples from people with ALS at early and later timepoints with healthy controls,” explained Dr. Murdock.  “We found widespread disruptions in immune-related genes, including reduced activity from the body’s usual immune response early in the disease and increased activity of different immune-related genes later in the disease.”

“These findings are important because they suggest that NK cells become increasingly altered as ALS progresses,” said Dr. Goutman.  “Targeting specific NK cell pathways may offer a promising new therapeutic strategy, and further work is needed to identify and understand the timing of such therapies.”

Other authors: Kai Guo, Ph.D., Jihyun Park, Ph.D., Dae-Gyu Jang, Ph.D., Samuel Teener, Ian Webber-Davis, Joshua Famie, and Caroline Piecuch, from the University of Michigan, and Junguk Hur, Ph.D., from University of North Dakota.

Support for this research includes the National Institutes of Health, National Institute of Neurological Disorders and Stroke, Department of Defense, ALS Association, Rober A. Epstein and Joan Chernoff-Epstein Emerging Scholar Fund, Dr. Randal Whitcomb Fund for ALS Genetics, Coleman Therapeutic Discovery Fund, Peter R. Clark Fund for ALS Research, James and Margaret Hiller, and Eric and Linda Novak.

Paper cited: Goutman SA, Guo K, Park J, Jang DG, Teener SJ, Webber-Davis IF, Famie JP, Piecuch CE, Hur J, Murdock BJ. Natural Killer Cell Dysregulation During ALS Disease Progression: A Gene Expression Analysis. Neurol Open Access. 2026 Mar;2(1):e000067. doi: 10.1212/wn9.0000000000000067. Epub 2026 Feb 9. PMID: 41684905; PMCID: PMC12893619.

In This Story

ben_murdock_labhds21094_small

Benjamin J Murdock, PhD

Research Assistant Professor

goutman

Stephen A Goutman, MD, MS, FAAN

Associate Professor

Featured News & Stories

Illustration of a line of people climbing a mountain whose summit is the Emerging Leaders Council
Illuminate

Emerging into the Future

The Rogel Cancer Center’s Emerging Leaders Council, launched in 2021, supports early-career faculty. Made up of 15 members, the council gives faculty a voice in sharing their needs with Rogel leadership while helping them learn how the cancer center operates, connect with senior leaders, and develop leadership skills.
News Release

Ljungman receives $500K from the Little Warrior Foundation for Ewing sarcoma gene-editing therapy

Mats Ljungman, Ph.D., professor of radiation oncology and environmental health sciences at the University of Michigan, received a $528,728 award from the Little Warrior Foundation to further research using a gene editing system to target a gene fusion involved in Ewing sarcoma.
Maize and blue 3D model of conjoined twins
Department News

3D-Printed Models - Conjoined Twins

Overview of 3D models for surgical planning
Heemskerk Lab Image
Research News

CPOD Faculty Publication Spotlight - Heemskerk Lab

In the February 2026 issue of Development, the Heemskerk Lab published "Endogenous FGFs drive ERK-dependent cell fate patterning in 2D human gastruloids."
3 Wishes CCMU Team Jakob McSparron, MD; Sara Didoszak MSN, RN; Diana Brown MSW; Maddie Lagina, MD, MPH; Abi Beutler RN
Department News

Critical Care Program Fulfills Patients’ Final Wishes, Bringing Comfort to Last Moments

Launched by our CCMU team in February 2025, the 3 Wishes Program helps patient-facing clinicians and staff honor and support patients nearing the end of life in the medical ICU. Since its inception, it has fulfilled more than 70 meaningful wishes, bringing comfort and lasting memories to patients and their families.
Emily Wittrup
Department News

Improving care for patients with brain injuries

Emily Wittrup defended her dissertation this May, marking a successful end to her PhD journey.